Trial Profile
A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Opaganib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors RedHill Biopharma
- 16 May 2019 Status changed from recruiting to discontinued.
- 14 Nov 2018 According to a RedHill Biopharma media release, enrollment for the Phase Ib portion of the study has been completed with a total of 11 patients enrolled and treated in three dose cohorts.
- 14 Nov 2018 According to a RedHill Biopharma media release, data will be presented at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.